Source:http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/991
| Predicate | Object |
|---|---|
| rdf:type | |
| rdfs:label |
Lotrisone (Lotion)
|
| dailymed-instance:dosage |
Gently massage sufficient LOTRISONE Cream or Lotion into the affected skin areas twice a day, in the morning and evening. LOTRISONE Cream or Lotion should not be used longer than 2 weeks in the treatment of tinea corporis or tinea cruris, and amounts greater than 45 g per week of LOTRISONE Cream or amounts greater than 45 mL per week of LOTRISONE Lotion should not be used. If a patient with tinea corporis or tinea cruris shows no clinical improvement after 1 week of treatment with LOTRISONE Cream or Lotion, the diagnosis should be reviewed. LOTRISONE Cream or Lotion should not be used longer than 4 weeks in the treatment of tinea pedis and amounts greater than 45 g per week of LOTRISONE Cream or amounts greater than 45 mL per week of LOTRISONE Lotion should not be used. If a patient with tinea pedis shows no clinical improvement after 2 weeks of treatment with LOTRISONE Cream or Lotion, the diagnosis should be reviewed. LOTRISONE Cream or Lotion should not be used with occlusive dressings.
|
| dailymed-instance:descripti... |
LOTRISONE Cream and Lotion contain combinations of clotrimazole, a synthetic antifungal agent, and betamethasone dipropionate, a synthetic corticosteroid, for dermatologic use. Chemically, clotrimazole is 1���(o-chloro-��,��-diphenylbenzyl) imidazole, with the empirical formula CHClN, a molecular weight of 344.84, and the following structural formula: Clotrimazole is an odorless, white crystalline powder, insoluble in water and soluble in ethanol. Betamethasone dipropionate has the chemical name 9-fluoro-11��,17,21-trihydroxy-16��-methylpregna-1,4-diene-3,20-dione 17,21-dipropionate, with the empirical formula CHFO, a molecular weight of 504.59, and the following structural formula: Betamethasone dipropionate is a white to creamy white, odorless crystalline powder, insoluble in water. Each gram of LOTRISONE Cream contains 10 mg clotrimazole and 0.643 mg betamethasone dipropionate (equivalent to 0.5 mg betamethasone), in a hydrophilic cream consisting of purified water, mineral oil, white petrolatum, cetyl alcohol plus stearyl alcohol, ceteareth-30, propylene glycol, sodium phosphate monobasic monohydrate, and phosphoric acid; benzyl alcohol as preservative. LOTRISONE Cream may contain sodium hydroxide. LOTRISONE Cream is smooth, uniform, and white to off-white in color. Each gram of LOTRISONE Lotion contains 10 mg clotrimazole and 0.643 mg betamethasone dipropionate (equivalent to 0.5 mg betamethasone), in a hydrophilic base of purified water, mineral oil, white petrolatum, cetyl alcohol plus stearyl alcohol, ceteareth-30, propylene glycol, sodium phosphate monobasic monohydrate, and phosphoric acid; benzyl alcohol as a preservative. LOTRISONE Lotion may contain sodium hydroxide. LOTRISONE Lotion is opaque and white in color.
|
| dailymed-instance:clinicalP... |
Clotrimazole and Betamethasone Dipropionate: LOTRISONE Cream has been shown to be at least as effective as clotrimazole alone in a different cream vehicle. No comparative studies have been conducted with LOTRISONE Lotion and clotrimazole alone. Use of corticosteroids in the treatment of a fungal infection may lead to suppression of host inflammation leading to worsening or decreased cure rate.<br/>Clotrimazole: Skin penetration and systemic absorption of clotrimazole following topical application of LOTRISONE Cream or Lotion have not been studied. The following information was obtained using 1% clotrimazole cream and solution formulations. Six hours after the application of radioactive clotrimazole 1% cream and 1% solution onto intact and acutely inflamed skin, the concentration of clotrimazole varied from 100 mcg/cmin the stratum corneum, to 0.5 to 1 mcg/cmin the reticular dermis, and 0.1 mcg/cmin the subcutis. No measurable amount of radioactivity (<0.001 mcg/mL) was found in the serum within 48 hours after application under occlusive dressing of 0.5 mL of the solution or 0.8 g of the cream. Only 0.5% or less of the applied radioactivity was excreted in the urine.<br/>Betamethasone Dipropionate: Betamethasone dipropionate, a corticosteroid, has been shown to have topical (dermatologic) and systemic pharmacologic and metabolic effects characteristic of this class of drugs.
|
| dailymed-instance:activeIng... | |
| dailymed-instance:contraind... |
LOTRISONE Cream or Lotion is contraindicated in patients who are sensitive to clotrimazole, betamethasone dipropionate, other corticosteroids or imidazoles, or to any ingredient in these preparations.
|
| dailymed-instance:supply |
LOTRISONE Cream is supplied in 15-g (NDC 0085-0924-01) and 45-g tubes (NDC 0085-0924-02); boxes of one. Store at 25��C (77��F); excursions permitted to 15�����30��C (59�����86��F) [see USP Controlled Room Temperature]. LOTRISONE Lotion is supplied in 30-mL bottles (NDC 0085-0809-01), box of one. Store at 25��C (77��F) in the upright position only; excursions permitted between 15��C and 30��C (59��F and 86��F). SHAKE LOTION WELL BEFORE EACH USE.
|
| dailymed-instance:activeMoi... | |
| dailymed-instance:inactiveI... |
dailymed-ingredient:benzyl_alcohol,
dailymed-ingredient:ceteareth-30,
dailymed-ingredient:cetyl_alcohol_plus_stearyl_alcohol,
dailymed-ingredient:mineral_oil,
dailymed-ingredient:phosphoric_acid,
dailymed-ingredient:propylene_glycol,
dailymed-ingredient:sodium_hydroxide,
dailymed-ingredient:sodium_phosphate_monobasic_monohydrate,
dailymed-ingredient:water,
dailymed-ingredient:white_petrolatum
|
| dailymed-instance:overdosag... |
Amounts greater than 45 g/week of LOTRISONE Cream or 45 mL/week of LOTRISONE Lotion should not be used. Acute overdosage with topical application of LOTRISONE Cream or Lotion is unlikely and would not be expected to lead to a life-threatening situation. LOTRISONE Cream or Lotion should not be used for longer than the prescribed time period. Topically applied corticosteroids, such as the one contained in LOTRISONE Cream or Lotion can be absorbed in sufficient amounts to produce systemic effects .
|
| dailymed-instance:genericMe... |
Clotrimazole and Betamethasone Dipropionate
|
| dailymed-instance:fullName |
Lotrisone (Lotion)
|
| dailymed-instance:adverseRe... |
Adverse reactions reported for LOTRISONE Cream in clinical trials were paresthesia in 1.9% of patients, and rash, edema, and secondary infection, each in less than 1% of patients. Adverse reactions reported for LOTRISONE Lotion in clinical trials were burning and dry skin in 1.6% of patients and stinging in less than 1% of patients. The following local adverse reactions have been reported with topical corticosteroids and may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, miliaria, capillary fragility (ecchymoses), and sensitization. In the pediatric population, reported adverse events for LOTRISONE Cream include growth retardation, benign intracranial hypertension, Cushing's syndrome (HPA axis suppression), and local cutaneous reactions, including skin atrophy. Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria in some patients. Adverse reactions reported with the use of clotrimazole are as follows: erythema, stinging, blistering, peeling, edema, pruritus, urticaria, and general irritation of the skin.
|
| dailymed-instance:indicatio... |
LOTRISONE Cream and Lotion are indicated in patients 17 years and older for the topical treatment of symptomatic inflammatory tinea pedis, tinea cruris, and tinea corporis due to Epidermophyton floccosum, Trichophyton mentagrophytes, and Trichophyton rubrum. Effective treatment without the risks associated with topical corticosteroid use may be obtained using a topical antifungal agent that does not contain a corticosteroid, especially for noninflammatory tinea infections. The efficacy of LOTRISONE Cream or Lotion for the treatment of infections caused by zoophilic dermatophytes (eg, Microsporum canis) has not been established. Several cases of treatment failure of LOTRISONECream in the treatment of infections caused by Microsporum canis have been reported.
|
| dailymed-instance:represent... | |
| dailymed-instance:routeOfAd... | |
| dailymed-instance:name |
Lotrisone
|